This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): BVF-025, JP-1730
Description: JP-1730 blocks the alpha-2 adrenergic receptor, thereby increasing the noradrenergic tone in the central nervous system by blocking the feedback inhibition mediated through presynaptic alpha-2 adrenoceptors. It may play a role in Parkinson disease, because in addition to the well-characterized loss of dopaminergic neurons, Parkinson disease is also accompanied by a significant loss of noradrenergic neurons in a part of the brain called the locus coeruleus. This is paralleled by a loss of noradrenaline fibers in the brain's cortex and a significant general depletion of noradrenaline in the brain.
Santhera and Juvantia
In September 2006, Santhera announced they have entered into a strategic collaboration to advance the development of Juvantia's fipamezole (JP-1730) for the treatment of Dyskinesia in Parkinson's Disease (DPD) patients. Santhera will be responsible for conducting and funding development work and has a call option to secure all rights to the product via the acquisition of all Juvantia shares at predetermined conditions any time before December 31, 2009. No further financial terms of the agreement were disclosed.
On August 17, 2009, Santhera announced that it exercised its option to acquire Juvantia Pharma.
Santhera and Biovail (Valeant)
On August 24, 2009, Santhera and Biovail announced that the two companies have signed a license agreement for Santhera's JP-1730/fipamezole. Biovail acquires the US and Canadian rights to develop and commercialize the drug for the treatment of Dyskinesia in Parkinson's Disease.
Under the terms of the...See full deal structure in Biomedtracker
Partners: Ipsen SA
Additional information available to subscribers only: